Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates

分组1 - Gossamer Bio reported a quarterly loss of $0.21 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, representing an earnings surprise of -7.14% [1] - The company posted revenues of $13.8 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 81.52%, compared to $9.38 million in the same quarter last year [2] - Gossamer Bio shares have declined approximately 85.3% since the beginning of the year, contrasting with the S&P 500's decline of 2.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $6.03 million, and for the current fiscal year, it is -$0.55 on revenues of $19.79 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8]